← FDA DRUG APPROVALS

FDA NDA · NDA219947

REDEMPLO

plozasiran

Sponsor: ARROWHEAD

APPLICATION
NDA219947
TYPE
NDA
ORIGINAL APPROVAL
2025-11-18
LATEST ACTION
2025-11-18
ROUTE
SUBCUTANEOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

REDEMPLO · ReferencePrescription
PLOZASIRAN SODIUM EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) · SOLUTION · SUBCUTANEOUS

Approval history

2025-11-18Type 1 - New Molecular Entity · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →